Azitra has been awarded a Phase II Small Business Innovation Research (SBIR) grant (#1853071) of $719,700 from the National Science Foundation (NSF). This grant will support the advanced development of AZT-02 for treating the rare genetic skin condition, Netherton syndrome (NS).
AZT-02 is a topical ointment composed of a proprietary strain of Staphylococcus epidermidis (SE), a bacterium naturally found in the skin microbiome. The product candidate is engineered to secret therapeutic levels of LEKTI, an essential protein missing in newborns affected by NS.